96 related articles for article (PubMed ID: 3390390)
21. [Clonogenic cultivation of bone marrow fibroblast precursors in human myeloproliferative diseases].
Kolosova LIu; Vladimirskaia EB; Kovaleva LG
Eksp Onkol; 1988; 10(2):46-8. PubMed ID: 3292215
[TBL] [Abstract][Full Text] [Related]
22. Platelet-derived growth factor(s) mitogenic activity in patients with myeloproliferative disease.
Bernabei PA; Arcangeli A; Casini M; Grossi A; Padovani R; Rossi Ferrini P
Br J Haematol; 1986 Jun; 63(2):353-7. PubMed ID: 3755056
[TBL] [Abstract][Full Text] [Related]
23. [Megakaryocytopoiesis in myeloproliferative disorders].
Podolak-Dawidziak M
Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
[No Abstract] [Full Text] [Related]
24. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor-beta 1 inhibitory effect of platelet-derived growth factor-induced signal transduction on human bone marrow fibroblasts: possible involvement of protein phosphatases.
Fontenay M; Bryckaert M; Tobelem G
J Cell Physiol; 1992 Sep; 152(3):507-19. PubMed ID: 1324246
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of myelofibrosis in chronic myeloproliferative disorders.
Yonekura S
Tokai J Exp Clin Med; 1987 Sep; 12(3):141-5. PubMed ID: 3331217
[No Abstract] [Full Text] [Related]
27. Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease.
Rueda F; Piñol G; Marti F; Pujol-Moix N
Acta Haematol; 1991; 85(1):12-5. PubMed ID: 1826402
[TBL] [Abstract][Full Text] [Related]
28. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
29. Megakaryocytopoiesis in vitro of patients with essential thrombocythaemia: effect of plasma and serum on megakaryocytic colony formation.
Komatsu N; Suda T; Sakata Y; Eguchi M; Kaji K; Saito M; Miura Y
Br J Haematol; 1986 Oct; 64(2):241-52. PubMed ID: 3490877
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
Macavei I; Galatâr N
Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
[TBL] [Abstract][Full Text] [Related]
31. Effect of platelet-derived growth factor and bone marrow-conditioned medium on the proliferation of human bone marrow-derived fibroblastoid colony-forming cells.
Hirata J; Kaneko S; Nishimura J; Motomura S; Ibayashi H
Acta Haematol; 1985; 74(4):189-94. PubMed ID: 3939058
[TBL] [Abstract][Full Text] [Related]
32. PDGF-AA, a potent mitogen for cardiac fibroblasts from adult rats.
Simm A; Nestler M; Hoppe V
J Mol Cell Cardiol; 1997 Jan; 29(1):357-68. PubMed ID: 9040050
[TBL] [Abstract][Full Text] [Related]
33. Effects of platelet derived growth factor, epidermal growth factor and transforming growth factor-beta on the growth of human marrow fibroblasts.
Kimura A; Katoh O; Kuramoto A
Br J Haematol; 1988 May; 69(1):9-12. PubMed ID: 3260107
[TBL] [Abstract][Full Text] [Related]
34. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent.
Agren MS; Steenfos HH; Dabelsteen S; Hansen JB; Dabelsteen E
J Invest Dermatol; 1999 Apr; 112(4):463-9. PubMed ID: 10201530
[TBL] [Abstract][Full Text] [Related]
35. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
Martyré MC; Magdelenat H; Bryckaert MC; Laine-Bidron C; Calvo F
Br J Haematol; 1991 Jan; 77(1):80-6. PubMed ID: 1998600
[TBL] [Abstract][Full Text] [Related]
36. Platelet-derived growth factor enhances in vitro erythropoiesis via stimulation of mesenchymal cells.
Delwiche F; Raines E; Powell J; Ross R; Adamson J
J Clin Invest; 1985 Jul; 76(1):137-42. PubMed ID: 4019772
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical evaluation of bone marrow lymphoid nodules in chronic myeloproliferative disorders.
Franco V; Florena AM; Aragona F; Campesi G
Virchows Arch A Pathol Anat Histopathol; 1991; 419(4):261-6. PubMed ID: 1949608
[TBL] [Abstract][Full Text] [Related]
38. Proliferative capacity of venous ulcer wound fibroblasts in the presence of platelet-derived growth factor.
Vasquez R; Marien BJ; Gram C; Goodwin DG; Menzoian JO; Raffetto JD
Vasc Endovascular Surg; 2004; 38(4):355-60. PubMed ID: 15306954
[TBL] [Abstract][Full Text] [Related]
39. Receptor induction regulates the synergistic effects of substance P with IL-1 and platelet-derived growth factor on the proliferation of bone marrow fibroblasts.
Rameshwar P; Poddar A; Zhu G; Gascón P
J Immunol; 1997 Apr; 158(7):3417-24. PubMed ID: 9120302
[TBL] [Abstract][Full Text] [Related]
40. [Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes].
Brière J; Kiladjian JJ; Peynaud-Debayle E
C R Seances Soc Biol Fil; 1996; 190(5-6):533-9. PubMed ID: 9074718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
